The tweet was deleted by the author.
But we saved everything 🙂.
Emergent Biosolutions has published research in Clinical and Translational Science evaluating the safety and pharmacokinetics of multiple-dose intranasal naloxone.
The findings contribute important evidence to inform future opioid overdose response strategies. The company continues to advance its research efforts to address opioid-related emergencies.
Emergent Biosolutions previously received a contract modification worth $64.5 million from ASPR to expand supply of botulism antitoxin. The company has emphasized its commitment to global community safety through scientific rigor and quality-driven partnerships. These efforts parallel its ongoing research into responses for opioid-related emergencies.